Citi analyst Joanne Wuensch lowered the firm’s price target on Abbott (ABT) to $140 from $155 and keeps a Buy rating on the shares following the Q4 report. The firm believes Abbott will need post better quarters in order for the stock to regain momentum.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABT:
- Abbott price target lowered to $122 from $146 at Wells Fargo
- Buy Rating on Abbott: Near‑Term Nutrition Headwinds Offset by High-Growth MedTech and Attractive 2026 Valuation
- Abbott Laboratories Earnings Call: Devices Offset Nutrition Drag
- Morning News Wrap-Up: Thursday’s Biggest Stock Market Stories!
- Midday Fly By: GE Aerospace reports Q4 beat, P&G reports mixed Q2